Moreover, according to Cattaneo et al., elevated B7-H3 corresponded to poor survival only in patients with proper HLA class I expression, possibly due to severely impaired immune anti-cancer responses in the absence of HLA class I. Considering that in patients with HLA class I present, the survival was better in the event of low B7-H3 expression, targeting B7-H3 could be a promising therapeutic strategy for patients with high HLA class I pancreatic cancer [66]. This evidence concerns the gene CD276 and pancreatic neoplasm.